

CASE STUDIES

Regenerative medicine

Perdita irreversibile di tessuti e cellule


Infarto del miocardio Ictus cerebrale Diabete m. Alzheimer

Anomalia irreversibile di tessuti e cellule

Malattie genetiche

Regenerative medicine

- 1. Ingegneria dei tessuti
- 2. Terapia cellulare
- 3. Terapia genica




Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts.

- knock out mice
- •Cloned gene
- •Genetically modified foetal cells

Muscular dystrophies

- Genetic disease
- Multiple genes involved; most common involving the dystrophin glyocprotein complex (DGC)
- · typical trait is fiber necrosis

Dystrophin-glycoprotein complex



Conventional therapy

> Stretching of muscles

⇒ Does not cure

> Corticosteroid treatment


⇒ Side effectes

> Drugs to induce protein symthesis similar to the absent (utrophin)

Mesoangioblasts


- Foetal stem cells associated with vascular system
- Highly proliferative
- Can move out of the vasculature in presence of inflammation
- Respond to mecrotic cytokines

alpha-sarcoglican expression after mesoangioblasts (10e5) wt, heterologous in female -/- mice. Analysis at 2 months.




 α -SG ab and tissue quality

alpha-SG in mesoangioblasts




Fish (in blue) shows Y (arrow head), and α -SG positive (red)

3 injections at 40 days intervals; 5 x 10⁵ mesoangioblasts male wt in female -/-. Assay 4 months after 1st injection




 α -SG (in red), absent in diseases animals, is visible in treated mice

Triple injection. Muscle functionality evaluated ex vivo




• Fibre section area

3 injections at 40 days intervals 5 x 10⁵ autologous **mesoangioblasts** (from -/- mice aged <u>15d</u>) <u>treated with lenti-PGK-SG-IRES-GFP</u>



IF and WB show GFP and α -SG


Assay of muscular force in treated mice



Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs

Maurilio Sampaolesi^{1,2}*, Stephane Blot³*, Giuseppe D'Antona², Nicolas Granger³, Rossana Tonlorenzi¹, Anna Innocenzi¹, Paolo Mognol⁴, Jean-Laurent Thibaud³, Beatriz G. Galvez¹, Ines Barthélémy³, Laura Perani¹, Sara Mantero⁴, Maria Guttinger⁵, Orietta Pansarasa², Chiara Rinaldi², M. Gabriella Cusella De Angelis², Yvan Torrente⁶, Claudio Bordignon¹, Roberto Bottinelli² & Giulio Cossu^{1,5,7}

Characterization of dog mesoangioblasts in vitro and in mice



Dog mesangio

A-morphology

B-proliferation


C-karyotype

D-F transduction microdystro an GFP lenti


G-migration into skeletal muscle

H-histology in scid-mdx mice (laminin, dystro)

Dogs (duchenne model) after intraartherial delivery of heterologous wt mesangioblasts




Histo (d-cured; a-c variable ill phehotype)




Immune histo on muscle

Quantitative analysis of dystrophin content in tissue from treated dogs



Physiology of treated dogs





http://www.telethon.it/comunicazione/cossu/Cossu.MP3